Business Context and Reporting Period
This Form 8-K Current Report was filed by BIOVIE INC. (f/k/a NanoAntibiotics, Inc.) on January 4, 2017. The filing discloses the entry into a material definitive agreement and unregistered sales of equity securities. The company is headquartered in Beverly, MA, and operates in the biopharmaceutical sector.
Key Financial Metrics and Transaction Details
The filing details a financing arrangement rather than standard operational financial results (revenue, profit, or cash flow) for a reporting period.
- Agreement Type: Common Stock Purchase Agreement and Registration Rights Agreement with Aspire Capital Fund, LLC.
- Total Commitment: Aspire Capital is committed to purchase up to $12.0 million of the Company's common stock over a 30-month term.
- Initial Proceeds: Upon execution, the Company sold 1,000,000 shares and warrants to purchase 500,000 shares for proceeds of $200,000.
- Warrant Terms: Five-year term, exercisable at $0.50 per share.
- Commitment Shares: The Company issued 2,400,000 shares of common stock to Aspire Capital as consideration for entering the agreement.
- Use of Proceeds: Expected to be used for working capital and general corporate purposes.
Material Changes and Pricing Mechanics
The filing establishes a new mechanism for equity financing with specific pricing and volume constraints:
- Purchase Price: The lesser of the lowest sale price on the purchase date or the arithmetic average of the three lowest closing sale prices during the 12 consecutive trading days preceding the purchase date.
- Volume Limits: The Company may direct purchases of up to 100,000 shares per business day.
- VWAP Option: If the closing price is $\ge$ $0.30, the Company may issue a Volume-Weighted Average Price (VWAP) Purchase Notice for up to 30% of the aggregate shares traded on the principal market, priced at 95% of the VWAP.
- Price Floor: No sales may occur if the closing sale price is less than $0.10.
- Control: The Company controls the timing and amount of sales; Aspire Capital has no right to require sales but is obligated to purchase as directed.
Guidance, Risks, and Contingencies
Management Commentary and Outlook: The Company intends to use the proceeds for working capital. The agreement allows the Company to terminate the Purchase Agreement at any time at its discretion without cost.
Risks and Contingencies:
- Forward-Looking Statements: The filing contains forward-looking statements regarding future sales and prices, which are subject to risks and uncertainties. Actual results may differ materially.
- Short-Selling Restrictions: Aspire Capital is prohibited from engaging in direct or indirect short-selling or hedging of the Company's stock during the term of the agreement.
- Registration: The issuance of shares is exempt from registration under Section 4(a)(2) of the Securities Act, though the Company agreed to file registration statements for the shares issued under the agreement.
- Regulatory Context: A press release referenced in the filing mentions FDA comments on an IND application, indicating ongoing regulatory interactions.
Investor Verification Checklist
- Verify the current market price of BIOVIE common stock relative to the $0.10 price floor and $0.30 VWAP trigger.
- Review the full text of the Common Stock Purchase Agreement (Exhibit 10.1) for specific conditions precedent to the $12.0 million commitment.
- Assess the dilution impact of the 2,400,000 Commitment Shares and potential future issuances up to $12.0 million.
- Monitor the status of the FDA comments on the IND application mentioned in the associated press release (Exhibit 99.1).
- Confirm the effectiveness of the registration statement required under the Registration Rights Agreement.